In a bid to bolster its immunology and respiratory pipeline, GSK has entered into a collaboration agreement with Flagship Pioneering in a deal worth up to US$7 B. Through the deal, the companies will work together to identify ten new medicines or vaccines, with an initial focus on respiratory and immunology indications. The alliance marks yet another big pharma partnership for Flagship, after signing similar partnerships with other big giants such as Pfizer and Novo Nordisk.